Corcept Therapeutics Inc.

Cortisol modulation company with Korlym (mifepristone) approved for Cushing's syndrome and next-generation relacorilant advancing as a selective cortisol modulator. Corcept's pipeline targets hypercortisolism and cortisol-driven conditions across endocrinology and oncology.